Rheumatoid Pachymeningitis: A Rare Complication of Rheumatoid Arthritis

ELENI TINIAKOU, MD, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; MARINOS KONTZIALIS, MD, Neuroradiology, Rush University Medical Center, Chicago, Illinois; MICHELLE PETRI, MD, MPH, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA. ET received support from Jerome Greene Foundation and Rheumatology Research Foundation. Address correspondence to Dr. E. Tiniakou, Johns Hopkins University School of Medicine, Division of Rheumatology, 5200 Eastern Ave., MFL Building, Center Tower, Suite 4100, Baltimore, Maryland 21224, USA. E-mail: etiniak1@jhmi.edu. Ethical approval was not required by the authors' institution (Johns Hopkins University). J Rheumatol 2018;45:1325–6; doi:10.3899/jrheum.171074

Rheumatoid pachymeningitis is a rare complication of rheumatoid arthritis (RA) and is a diagnosis of exclusion^{1,2}.

A 57-year-old male from El Salvador with a history of longstanding seropositive, nonerosive RA and interstitial lung disease, who was noncompliant with medical treatment, presented with severe occipital headache for about 8 months. The headache was associated with photophobia, phonophobia, and nausea, and was exacerbated by bending, laying supine, and coughing. Serologic evaluation was positive for high-titer rheumatoid factor/ cyclic citrullinated peptide, elevated inflammatory markers, negative antinuclear anti-

bodies and antineutrophil cytoplasmic antibodies. Several lumbar punctures were performed, showing negative gram stain, normal glucose and protein, and mild mononuclear pleocytosis. Cerebrospinal fluid (CSF) cytology was negative, as were CSF mycobacterial, spirochetal, other bacterial, fungal, and viral studies. Magnetic resonance imaging of the brain and spine demonstrated pachymeningeal enhancement (Figure 1). Biopsy of the dura was inconclusive, with no specific pathologic changes.

Given the aforementioned negative infectious investigations and no evidence of systemic malignancy, the diagnosis

Figure 1. Coronal fat-suppressed postcontrast T1-weighted images (A, B) through the brain demonstrate abnormal pachymeningeal enhancement involving the floor of the right anterior cranial fossa and the left frontal convexity (arrows in A), and along the bilateral tentorial leaflets and the right lateral aspect of the posterior fossa (arrows in B). The punctate foci of enhancement in the frontal lobe are because of an incidental developmental venous anomaly (A). Sagittal postcontrast T1-weighted image of the thoracic spine (C) shows pachymeningeal enhancement along the anterior aspect of the thecal sac (arrows in C).

of rheumatoid pachymeningitis was entertained. The patient was given intravenous methylprednisolone 1 g daily for a total of 3 days, with rapid improvement of the patient's symptoms. He was discharged on a tapering regimen of prednisone and began taking methotrexate 15 mg weekly, with a plan to increase to 20 mg.

Early detection of rheumatoid pachymeningitis and initiation of steroids are essential to prevent neurological complications^{3,4}.

REFERENCES

1. Jones SE, Belsley NA, McLoud TC, Mullins ME. Rheumatoid meningitis: radiologic and pathologic correlation. *AJR Am J Roentgenol* 2006;186:1181-3.
2. Cianfoni A, Falcone C, Faustini F, Lauriola L, Imbesi S, Della Marca G, et al. Rheumatoid leptomeningitis: magnetic resonance imaging and pathologic findings — a case report. *J Neuroimaging* 2010;20:192-4.
3. Servioli MJ, Chugh C, Lee JM, Biller J. Rheumatoid meningitis. *Front Neurol* 2011;2:84.
4. Starosta MA, Brandwein SR. Clinical manifestations and treatment of rheumatoid pachymeningitis. *Neurology* 2007;68:1079-80.